- Home
- BGSF vs MREO Comparison
BGSF vs MREO Comparison
Compare BGSF & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BGSF | MREO |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.4M | 67.5M |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BGSF | MREO |
|---|---|---|
| Price | $6.07 | $0.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $9.00 | $3.13 |
| AVG Volume (30 Days) | 24.1K | ★ 1.5M |
| Earning Date | 03-11-2026 | 03-19-2026 |
| Dividend Yield | ★ 32.36% | N/A |
| EPS Growth | ★ 67.37 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $272,499,000.00 | $500,000.00 |
| Revenue This Year | $4.67 | N/A |
| Revenue Next Year | N/A | $6,363.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.91 | $0.20 |
| 52 Week High | $8.20 | $2.94 |
Technical Indicators
Market Signals| Indicator | BGSF | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 54.39 | 34.82 |
| Support Level | $5.93 | $0.20 |
| Resistance Level | $6.38 | $0.42 |
| Average True Range (ATR) | 0.26 | 0.03 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 39.77 | 22.62 |
Price Performance
Historical ComparisonAbout BGSF BGSF Inc.
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).